Hanne Struyfs
Overview
Explore the profile of Hanne Struyfs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wittens M, Denissen S, Sima D, Fransen E, Niemantsverdriet E, Bastin C, et al.
Alzheimers Res Ther
. 2024 Jun;
16(1):128.
PMID: 38877568
Objectives: This study aimed to evaluate the potential clinical value of a new brain age prediction model as a single interpretable variable representing the condition of our brain. Among many...
2.
Giraldo D, Smith R, Struyfs H, Niemantsverdriet E, De Roeck E, Bjerke M, et al.
J Alzheimers Dis
. 2022 Nov;
90(4):1771-1791.
PMID: 36336929
Background: Most studies using diffusion-weighted MRI (DW-MRI) in Alzheimer's disease (AD) have focused their analyses on white matter (WM) microstructural changes using the diffusion (kurtosis) tensor model. Although recent works...
3.
Bridel C, Somers C, Sieben A, Rozemuller A, Niemantsverdriet E, Struyfs H, et al.
Brain
. 2022 Jan;
145(11):4056-4064.
PMID: 35026840
Alzheimer's disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ1-42), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer's disease...
4.
Wittens M, Sima D, Houbrechts R, Ribbens A, Niemantsverdriet E, Fransen E, et al.
J Alzheimers Dis
. 2021 Aug;
83(2):623-639.
PMID: 34334402
Background: Magnetic resonance imaging (MRI) has become important in the diagnostic work-up of neurodegenerative diseases. icobrain dm, a CE-labeled and FDA-cleared automated brain volumetry software, has shown potential in differentiating...
5.
Struyfs H, Sima D, Wittens M, Ribbens A, Pedrosa de Barros N, Phan T, et al.
Neuroimage Clin
. 2020 Mar;
26:102243.
PMID: 32193172
Brain volumes computed from magnetic resonance images have potential for assisting with the diagnosis of individual dementia patients, provided that they have low measurement error and high reliability. In this...
6.
Ng K, Therriault J, Kang M, Struyfs H, Pascoal T, Mathotaarachchi S, et al.
Neuroimage Clin
. 2019 Dec;
24:102091.
PMID: 31795034
Background: [F]THK5351 is a tau positron emission tomography tracer that has shown promise in quantifying tau distribution in tauopathies such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). However,...
7.
Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, et al.
Neuroimage Clin
. 2019 Mar;
22:101771.
PMID: 30927601
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is...
8.
Niemantsverdriet E, Ribbens A, Bastin C, Benoit F, Bergmans B, Bier J, et al.
J Alzheimers Dis
. 2018 May;
63(4):1509-1522.
PMID: 29782314
Background: Magnetic resonance imaging (MRI) acquisition/processing techniques assess brain volumes to explore neurodegeneration in Alzheimer's disease (AD). Objective: We examined the clinical utility of MSmetrix and investigated if automated MRI...
9.
Mattsson N, Groot C, Jansen W, Landau S, Villemagne V, Engelborghs S, et al.
Alzheimers Dement
. 2018 Mar;
14(7):913-924.
PMID: 29601787
Introduction: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid...
10.
Therriault J, Ng K, Pascoal T, Mathotaarachchi S, Kang M, Struyfs H, et al.
Neurology
. 2018 Feb;
90(11):e932-e939.
PMID: 29444971
Objective: To identify the pathophysiologic mechanisms and clinical significance of anosognosia for cognitive decline in mild cognitive impairment. Methods: We stratified 468 patients with amnestic mild cognitive impairment into intact...